Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.49 |
| ▸ | GUCY1A1 | Q02108 | 3/20 | 0.47 |
| ▸ | GUCY1B1 | Q02153 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15502896 | 0.89 | HTT (0.52) | MAPTHTTSMN1; SMN2KMT2AHPGD | |
| SCHEMBL15503009 | 0.88 | RAB9A (0.52) | MAPTHTTSMN1; SMN2KMT2AHPGD | |
| SCHEMBL3041788 | 0.88 | NPC1 (0.67) | MAPTHTTSMN1; SMN2KMT2AHPGD | |
| SCHEMBL15502857 | 0.87 | HTT (0.50) | MAPTHTTSMN1; SMN2KMT2AHPGD | |
| SCHEMBL17395647 | 0.85 | MAPT (0.55) | MAPTHTTSMN1; SMN2KMT2AHPGD | |
| SCHEMBL1782567 | 0.85 | GUCY1A1 (0.62) | MAPTHTTSMN1; SMN2KMT2AHPGD | |
| SCHEMBL3033818 | 0.84 | GUCY1A1 (0.54) | MAPTHTTSMN1; SMN2KMT2AHPGD | |
| SCHEMBL10514042 | 0.84 | HTT (0.50) | MAPTHTTSMN1; SMN2KMT2AHPGD | |
| SCHEMBL15507453 | 0.84 | HTT (0.47) | MAPTHTTSMN1; SMN2KMT2AHPGD | |
| SCHEMBL7232416 | 0.81 | NPC1 (0.50) | MAPTHTTSMN1; SMN2KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10550102-B2 | Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators | NOVARTIS AG (CH) | 2020-02-04 | — | — | US | disclosed |
| US-20190119254-A1 | INDANE AND INDOLINE DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2019-04-25 | — | — | US | disclosed |
| EP-3164395-B1 | INDANE AND INDOLINE DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | NOVARTIS AG (CH) | 2019-03-27 | — | — | EP | disclosed |
| US-10208018-B2 | Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators | NOVARTIS AG (CH) | 2019-02-19 | — | — | US | disclosed |
| US-10208018-B2 | Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators | NOVARTIS AG (CH) | 2019-02-19 | — | — | US | disclosed |
| US-9765067-B2 | Thiophen-2-yl-pyridin-2-yl-1H-pyrazole-4-carboxylic acid derivatives and the use thereof as soluble guanylate cyclase activators | NOVARTIS AG (CH) | 2017-09-19 | — | — | US | disclosed |
| US-9765067-B2 | Thiophen-2-yl-pyridin-2-yl-1H-pyrazole-4-carboxylic acid derivatives and the use thereof as soluble guanylate cyclase activators | NOVARTIS AG (CH) | 2017-09-19 | — | — | US | disclosed |
| EP-2683710-B1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | BOEHRINGER INGELHEIM INT (DE) | 2017-07-19 | — | — | EP | disclosed |
| US-20170197950-A1 | THIOPHEN-2-YL-PYRIDIN-2-YL-1H-PYRAZOLE-4-CARBOXYLIC ACID DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | NOVARTIS AG (CH) | 2017-07-13 | — | — | US | disclosed |
| US-20170197950-A1 | THIOPHEN-2-YL-PYRIDIN-2-YL-1H-PYRAZOLE-4-CARBOXYLIC ACID DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | NOVARTIS AG (CH) | 2017-07-13 | — | — | US | disclosed |
| US-20170197940-A1 | INDANE AND INDOLINE DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | NOVARTIS AG (CH) | 2017-07-13 | — | — | US | disclosed |
| US-20170197950-A1 | THIOPHEN-2-YL-PYRIDIN-2-YL-1H-PYRAZOLE-4-CARBOXYLIC ACID DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | NOVARTIS AG (CH) | 2017-07-13 | — | — | US | disclosed |
| US-20170197940-A1 | INDANE AND INDOLINE DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | NOVARTIS AG (CH) | 2017-07-13 | — | — | US | disclosed |
| US-8569339-B2 | Soluble guanylate cyclase activators | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-29 | — | — | US | disclosed |
| US-8569339-B2 | Soluble guanylate cyclase activators | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-29 | — | — | US | disclosed |
| US-20130065918-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-03-14 | — | — | US | disclosed |
| US-20130065918-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-03-14 | — | — | US | disclosed |
| WO-2012122340-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-09-13 | — | — | WO | disclosed |
| WO-2009071504-A1 | 2,6-DISUBSTITUTED PYRIDINES AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009071504-A1 | 2,6-DISUBSTITUTED PYRIDINES AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197940-A1 | INDANE AND INDOLINE DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | GUCY1A2, GUCY1A1, PDE3A | MAPT 2784/4885HTT 2957/4885SMN1; SMN2 2413/4885 |
| US-20130065918-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | GUCY1A1, GUCY1A2, GUCY1B1 | MAPT 4353/4885HTT 2679/4885SMN1; SMN2 832/4885 |
| US-10550102-B2 | Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators | GUCY1A2, GUCY1A1, PDE3A | MAPT 2784/4885HTT 2957/4885SMN1; SMN2 2413/4885 |
| US-10208018-B2 | Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators | GUCY1A2, GUCY1A1, PDE3A | MAPT 2784/4885HTT 2957/4885SMN1; SMN2 2413/4885 |
| US-20190119254-A1 | INDANE AND INDOLINE DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | GUCY1A2, GUCY1A1, PDE3A | MAPT 2784/4885HTT 2957/4885SMN1; SMN2 2413/4885 |
| US-20170197950-A1 | THIOPHEN-2-YL-PYRIDIN-2-YL-1H-PYRAZOLE-4-CARBOXYLIC ACID DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | GUCY1B2, GUCY1A2, GUCY1A1 | MAPT 3284/4885HTT 2612/4885SMN1; SMN2 1463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.